

2ª Convocatoria de “Acceso competitivo” a NANBIOSIS de 2026

Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS

por del Comité de Coordinación

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado y acceder en las modalidades de “Acceso Abierto Competitivo” o “Acceso por Demanda” para usuarios del sector público o sólo en la modalidad de “Acceso por Demanda” para usuarios del sector privado.

Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en “acceso por demanda”. Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 1ª Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2026, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación de solicitudes y la propuesta de priorización emitida por el Comité de Acceso, acuerda:

- Conceder acceso priorizado en “modo abierto y competitivo” a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación.
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla).
- Dejar en reserva como candidatos a ser considerados como los accesos en régimen abierto y competitivo los derivados de solicitudes en naranja, las cuales cumplen con los requisitos de admisión en esta modalidad, pero que, por estar ya completa la capacidad de la unidad reservada a tal modalidad, se propone que queden en reserva para ser consideradas como acceso abierto, y obtener los beneficios de esta modalidad, en caso de que finalmente no se puedan ejecutar los accesos de las solicitudes que han quedado por delante en la lista de priorización
- Considerar como “accesos a demanda” los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos

derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los "accesos competitivos".

Priorización de Solicitudes de Acceso a NANBIOSIS

Unidad	Solicitud	Descripción	Puntos
U01 (en colaboración con U30)	4891	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING. U30-S03. Protein identification by mass spectrometry (MS) or MS/MS	9
U01	4895	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING, U1-S03: Protein purification (On-site & Remote) OUTSTANDING	5
U01	4897	U1-S03: Protein purification (On-site & Remote) OUTSTANDING	5
U01	4898	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING, U1-S03: Protein purification (On-site & Remote) OUTSTANDING	5
U01	4893	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING, U1-S03: Protein purification (On-site & Remote) OUTSTANDING	0
U01	4894	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING, U1-S03: Protein purification (On-site & Remote) OUTSTANDING	0
U01	4896	U1-S03: Protein purification (On-site & Remote) OUTSTANDING	0
U01	4899	U1-S04: Consultancy in protein production (On-site & Remote)	0
U01	4900	U1-S03: Protein purification (On-site & Remote) OUTSTANDING	0
U01	4911	U1-S03: Protein purification (On-site & Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U02	4923	U2-S05. Monoclonal Antibody development (Remote) OUTSTANDING	5
U02	4927	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S07. Antibody purification (Remote) OUTSTANDING	5
U02	4942	U2-S06. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S07. Antibody purification (Remote) OUTSTANDING	5
U02	4926	U2-S04. Polyclonal Antibody Production (Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U03 (en colaboración con U06)	4908	U3-S01. Synthesis of peptides and characterisation (On-site & Remote) OUTSTANDING. U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration	9

Unidad	Solicitud	Descripción	Puntos
U06 (en colaboración con U16)	4903	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration. U16-S07. Evaluation of the adhesion capacities and formation of biolayers of microorganisms on materials. OUTSTANDING	9
U06 (en colaboración con U03)	4908	U3-S01. Synthesis of peptides and characterisation (On-site & Remote) OUTSTANDING. U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration	9
U06 (en colaboración con U20)	4918	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration. U20-S04. Hemocompatibility assays: haemolysis, platelet aggregation, plasma coagulation times and complement activation, U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S11. In vivo PK/PD assays (Remote) OUTSTANDING	9
U06	4830	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	5
U06	4902	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote)	5

		OUTSTANDING, U6-S02. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	
U06	4905	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S02. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S06. Pulse-free microfluidic system, U6-S08. Tangential flow filtration, U6-S09. Multimode plate reader	5
U06	4849	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	1
U06	4859	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	1
U06	4940	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	1
U06	4845	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	0
U06	4862	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	0
U06	4950	U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U07	4919	U7-S01. Training Courses in the Use of Nanotechnology Equipment (Onsite)	5
U07	4920	U7-S09. Thin layer deposition (Remote) OUTSTANDING	5
U07	4937	U7-S03. Characterization by SEM (On-site & Remote) OUTSTANDING, U7-S07. Photolithography and soft-lithography manufacturing processes (On-site & Remote) OUTSTANDING, U7-S08. Fabrication of Chromium masks (Remote) OUTSTANDING, U7-S09. Thin layer deposition (Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site & Remote)	5
U07	4936	U7-S01. Training Courses in the Use of Nanotechnology Equipment (Onsite)	1
U07	4884	U7-S03. Characterization by SEM (On-site & Remote) OUTSTANDING, U7-S07. Photolithography and soft-lithography manufacturing processes (On-site & Remote) OUTSTANDING	0
U07	4933	U7-S01. Training Courses in the Use of nanotechnology equipment (Onsite)	0

Unidad	Solicitud	Descripción	Puntos
--------	-----------	-------------	--------

U12	4939	U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING	8
U12	4836	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING	7
U12	4829	U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING	5
U12	4865	U12-S06. Surface hydrophobicity characterization (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING	5
U12	4916	U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING	5
U12	4965	U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING	5
U12	4842	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U13	4972	U13-S05. UNIAXIAL TENSILE TEST INSTRON MicroTester (Remote) OUTSTANDING	5

Unidad	Solicitud	Descripción	Puntos
U14	4860	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING	5
U14 (en colaboración con U21, U22 y U24)	4863	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U14 (en colaboración con U21, U22 y U24)	4866	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5

U14	4873	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING	5
U14 (en colaboración con U24)	4883	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U14 (en colaboración con U22, U23)	4912	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING.	5
U14, (en colaboración con U19, U21, U22, U23, U24)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U14 (en colaboración con U19, U21, U22, U24)	4858	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING. U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U14 (en colaboración con U24)	4901	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	2

U14	4856	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING	0
U14	4857	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U16 (en colaboración con U06)	4903	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration. U16-S07. Evaluation of the adhesion capacities and formation of bilayers of microorganisms on materials. OUSTANDING	9
U16	4828	U16-S01. XPS (Remote) OUTSTANDING	5
U16	4837	U16-S01. XPS (Remote) OUTSTANDING	5
U16	4913	U16-S05. DROP SHAPE ANALYZER – DSA100E – Goniometer - (Remote) OUTSTANDING, U16-S06. 3D Optical Surface Metrology System Leica DCM8 – Optical profilometer- (Remote) OUTSTANDING, U16-S08. Electrical characterisation of surfaces through the determination of zeta potential., U16-S09. Kelvin Probe Force Microscopy (KPFM)	5
U16	4838	U16-S01. XPS (Remote) OUTSTANDING	1
U16	4848	U16-S06. 3D Optical Surface Metrology System Leica DCM8 – Optical profilometer- (Remote) OUTSTANDING	1
U16	4914	U16-S06. 3D Optical Surface Metrology System Leica DCM8 – Optical profilometer- (Remote) OUTSTANDING, U16-S07. Evaluation of the adhesion capacities and formation of bilayers of microorganisms on materials. OUSTANDING	1
U16	4915	U16-S05. DROP SHAPE ANALYZER – DSA100E – Goniometer - (Remote) OUTSTANDING, U16-S06. 3D Optical Surface Metrology System Leica DCM8 – Optical profilometer- (Remote) OUTSTANDING, U16-S08. Electrical characterisation of surfaces through the determination of zeta potential.	1

Unidad	Solicitud	Descripción	Puntos
U17	4850	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING	5
U17	4888	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
--------	-----------	-------------	--------

U18	4875	U18-S01. In vitro Toxicology (Remote) OUTSTANDING	5
U18	4876	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	5
U18	4877	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	5
U18	4880	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	5
U18	4889	U18-S01. In vitro Toxicology (Remote) OUTSTANDING	5
U18	4867	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4868	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4869	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4870	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4871	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4872	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING	2
U18	4879	U18-S01. In vitro Toxicology (Remote) OUTSTANDING	1

Unidad	Solicitud	Descripción	Puntos
U19 (en colaboración con U21, U22 y U24)	4839	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U19 (en colaboración con U21, U22 y U24)	4840	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U19 (en colaboración con U21, U22 y U24)	4864	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U19, (en colaboración con U14, U21, U22, U23 y U24)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of	5

		nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	
U19 (en colaboración con U22)	4874	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote). U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site). .	4
U19 (en colaboración con U21, U22 y U24)	4925	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	3
U19 (en colaboración con U14, U21, U22, U24)	4858	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING. U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2

U19 (en colaboración con U21, U22, U23)	4917	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U19 (en colaboración con U21, U22 y U24)	4946	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote). U24-S02. Medical Imaging for Minimal Invasive Surgery	1

Unidad	Solicitud	Descripción	Puntos
U20 (en colaboración con U06)	4918	U6-S01. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S04. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site & Remote) OUTSTANDING, U6-S05. Freeze dryer, U6-S08. Tangential flow filtration. U20-S04. Hemocompatibility assays: haemolysis, platelet aggregation, plasma coagulation times and complement activation, U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S11. In vivo PK/PD assays (Remote) OUTSTANDING	9
U20	4831	U20-S015. Cytotoxicity: proliferation, LDH, apoptosis and ROS	5
U20	4832	U20-S015. Cytotoxicity: proliferation, LDH, apoptosis and ROS	5
U20	4833	U20-S05. In vitro Efficacy assays of drugs, nanomedicines, biomaterials and others	5
U20	4834	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	5
U20	4843	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	5
U20	4882	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	5
U20	4892	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	5

U20	4941	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	5
U20	4943	U20-S06. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	5
U20	4890	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	2
U20	4945	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S06. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S10. In vivo ADME and biodistribution assays (Remote) OUTSTANDING	2
U20	4844	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING	0
U20	4885	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S02. Preclinical Experimental consultancy (Remote) OUTSTANDING, U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S09. In vivo toxicology (On-site & Remote) OUTSTANDING	0
U20	4886	U20-S01. Histological processing, section, staining and immunohistochemistry assays (Remote) OUTSTANDING, U20-S02. Preclinical Experimental consultancy (Remote) OUTSTANDING, U20-S07. Animal models in oncology (Orthotopic, subcutaneous, intrasplenic and intravenous cell inoculation in syngeneic and immunodeficient mice (Remote) OUTSTANDING, U20-S08. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S09. In vivo toxicology (On-site & Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U21 (en colaboración con U22 y U24)	4841	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	8

U21 (en colaboración con U19, U22 y U24)	4839	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U21 (en colaboración con U19, U22 y U24)	4840	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U21 (en colaboración con U14, U22 y U24)	4863	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U21 (en colaboración con U19, U22 y U24)	4864	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U21 (en colaboración con U14, U22 y U24)	4866	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U21, (en colaboración con U14, U19, U22, U23, U24)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5

U21 (en colaboración con U19, U22 y U24)	4925	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	3
U21 (en colaboración con U14, U19, U22, U24)	4858	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING. U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U21 (en colaboración con U19, U22, U23 y U24)	4917	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U21 (en colaboración con U22 y U24)	4944	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2

U21 (en colaboración con U22, U23 y U24)	4935	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S03. Micromanipulation and microinjection (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	1
U21 (en colaboración con U19, U22 y U24)	4946	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote). U24-S02. Medical Imaging for Minimal Invasive Surgery	1

Unidad	Solicitud	Descripción	Puntos
U22 (en colaboración con U21 y U24)	4841	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	8
U22 (en colaboración con U19, U21 y U24)	4839	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U22 (en colaboración con U19, U21 y U24)	4840	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U22 (en colaboración con U14, U21 y U24)	4863	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U22 (en colaboración con U19, U21 y U24)	4864	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U22 (en colaboración con U14, U21 y U24)	4866	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5

U22, (en colaboración con U14, U23)	4912	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING.	5
U22, (en colaboración con U14, U19, U21, U23, U24)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U22 (en colaboración con U19)	4874	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote). U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site). .	4
U22 (en colaboración con U19, U21 y U24)	4925	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	3

U22 (en colaboración con U14, U19, U21, U24)	4858	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING. U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U22 (en colaboración con U19, U21, U23 y 24)	4917	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U22 (en colaboración con U21 y U24)	4944	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U22 (en colaboración con U21, U23 y U24)	4935	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S03. Micromanipulation and microinjection (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	1
U22 (en colaboración con U19, U21 y U24)	4946	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote). U24-S02. Medical Imaging for Minimal Invasive Surgery	1

Unidad	Solicitud	Descripción	Puntos
U23, (en colaboración con U14, U22)	4912	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING.	5
U23, (en colaboración con U14, U19, U21, U22, U24)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U23 (en colaboración con U19, U21, U22 y U24)	4917	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U23 (en colaboración con U21, U22 y U24)	4935	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S03. Micromanipulation and microinjection (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	1

Unidad	Solicitud	Descripción	Puntos
U24 (en colaboración con U21 y U22)	4841	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	8

U24 (en colaboración con U19, U21 y U22)	4839	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U24 (en colaboración con U19, U21 y U22)	4840	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5
U24 (en colaboración con U14, U21 y U22)	4863	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U24 (en colaboración con U19, U21 y U22)	4864	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U24 (en colaboración con U14, U21 y U22)	4866	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U24 (en colaboración con U14)	4883	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	5
U24, (en colaboración con U14, U19, U21, U22, U23)	4921	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING. U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S01. In vitro fertilisation studies and embryo culture media viability (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	5

U24 (en colaboración con U14, U19, U21, U22)	4858	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING, U14-S02. Flow Cytometry (On-site & Remote) OUTSTANDING, U14-S04. Cytokine quantification assays (On-site & Remote) OUTSTANDING, U14-S05. Determination of cytokine concentration by flow cytometry (On-site & Remote) OUTSTANDING, U14-S06. Lymphocyte proliferation assay (On-site & Remote) OUTSTANDING. U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U24 (en colaboración con U14)	4901	U14-S01. Cell cultures (On-site & Remote) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease	2
U24 (en colaboración con U19, U21, U22 y U23)	4917	U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING. U23-S02. Embryo culture media viability studies (On-site & Remote) OUTSTANDING, U23-S04. Sperm, Oocyte and embryo cryopreservation (On-site & Remote) OUTSTANDING, U23-S05. In vitro Maturation (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U24 (en colaboración con U19, U21 y U22)	4925	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING. U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	3

U24 (en colaboración con U21 y U22)	4944	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	2
U24 (en colaboración con U21, U22 y U23)	4935	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING. U23-S03. Micromanipulation and microinjection (On-site & Remote) OUTSTANDING. U24-S02. Medical Imaging for Minimal Invasive Surgery	1
U24 (en colaboración con U19, U21 y U22)	4946	U19-S01. Preclinical Studies (On-site & Remote) OUTSTANDING, U19-S02. Animal Model Studies (On-site & Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site & Remote) OUTSTANDING. U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING. U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site & Remote). U24-S02. Medical Imaging for Minimal Invasive Surgery	1

Unidad	Solicitud	Descripción	Puntos
U25	4922	U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (On-site & Remote) OUTSTANDING, U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4928	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4929	U25-S09. Access to specific software and database (Remote) OUTSTANDING	5
U25	4930	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4931	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4932	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4934	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	5
U25	4924	U25-S05. Preclinical horizontal spectrometer Biospec 7T (On-site & Remote) OUTSTANDING	1

Unidad	Solicitud	Descripción	Puntos
U26	4958	U26-S06. Biomedical and metabolomic imaging (On-site)	7
U26	4963	U26-S06. Biomedical and metabolomic imaging (On-site)	7
U26	4964	U26-S06. Biomedical and metabolomic imaging (On-site)	7
U26	4907	U26-S04. In vivo NMR of small animals, zebrafish, Drosophila (Remote) OUTSTANDING	5

U26	4909	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING	5
U26	4910	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING	5
U26	4949	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING	5
U26	4951	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING, U26-S02. NMR experiments in solid state (Remote) OUTSTANDING, U26-S03. Metabolomic Studies (Remote) OUTSTANDING, U26-S04. In vivo NMR of small animals, zebrafish, Drosophila (Remote) OUTSTANDING, U26-S05. Training Advice and Assistance (On-site & Remote), U26-S06. Biomedical and metabolomic imaging (On-site)	5
U26	4952	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING, U26-S02. NMR experiments in solid state (Remote) OUTSTANDING, U26-S03. Metabolomic Studies (Remote) OUTSTANDING, U26-S04. In vivo NMR of small animals, zebrafish, Drosophila (Remote) OUTSTANDING, U26-S05. Training Advice and Assistance (On-site & Remote), U26-S06. Biomedical and metabolomic imaging (On-site)	5
U26	4953	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING, U26-S02. NMR experiments in solid state (Remote) OUTSTANDING, U26-S03. Metabolomic Studies (Remote) OUTSTANDING, U26-S04. In vivo NMR of small animals, zebrafish, Drosophila (Remote) OUTSTANDING, U26-S05. Training Advice and assistance (On-site & Remote), U26-S06. Biomedical and metabolomic imaging (On-site)	5
U26	4881	U26-S01. Acquisition of mono and bidimensional spectra (On-site & Remote) OUTSTANDING	1

Unidad	Solicitud	Descripción	Puntos
U27	4947	U27-S01. Remote access to HPC (On-site & Remote)	5
U27	4948	U27-S03. Biomedical signals processing, especially in cardiology (On-site & Remote) OUTSTANDING	5

Unidad	Solicitud	Descripción	Puntos
U28	4835	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S04. High Resolution Liquid NMR (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)	5

U28	4846	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)	5
U28	4847	U28-S02. Fluorescent and Bioluminescent Optical Imaging (On-site & Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote), U28-S08. Cryo-TEM (On-site & Remote) OUTSTANDING, U28-S010. Scanning Electron Microscopy (SEM) (On-site & Remote), U28-S016. Confocal Microscopy (On-site & Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (On-site & Remote)	5
U28	4904	U28-S07. Transmission Electron Microscopy (TEM) (On-site & Remote)	1
U28	4853	U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (On-site & Remote)	0
U28	4861	U28-S04. High Resolution Liquid NMR (On-site & Remote) OUTSTANDING	0
U28	4878	U28-S04. High Resolution Liquid NMR (On-site & Remote) OUTSTANDING	0

Unidad	Solicitud	Descripción	Puntos
U29	4852	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING	5
U29	4851	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING	1

Unidad	Solicitud	Descripción	Puntos
U30 (en colaboración con U01)	4891	U1-S02. Bioproduction of proteins (On-site & Remote) OUTSTANDING. U30-S03. Protein identification by mass spectrometry (MS) or MS/MS	9
U30	4959	U30-S08. Luminex or ELISA assay development and analysis	5
U30	4962	U30-S08. Luminex or ELISA assay development and analysis, U30-S09. Data analysis of proteomics experiments	5
U30	4966	U30-S01. Sample preparation for proteomic analysis, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S07. Protein separation by one- or two-dimensional gel electrophoresis, U30-S09. Data analysis of proteomics experiments	5

U30	4968	U30-S01. Sample preparation for proteomic analysis, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S07. Protein separation by one- or two-dimensional gel electrophoresis, U30-S09. Data analysis of proteomics experiments	5
U30	4969	U30-S08. Luminex or ELISA assay development and analysis, U30-S09. Data analysis of proteomics experiments	5
U30	4970	U30-S08. Luminex or ELISA assay development and analysis, U30-S09. Data analysis of proteomics experiments	5
U30	4957	U30-S01. Sample preparation for proteomic analysis, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS, U30-S09. Data analysis of proteomics experiments	1
U30	4960	U30-S01. Sample preparation for proteomic analysis, U30-S02. Determination of molecular mass of peptides, proteins and other biomolecules, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS	0
U30	4961	U30-S01. Sample preparation for proteomic analysis, U30-S02. Determination of molecular mass of peptides, proteins and other biomolecules, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS	0
U30	4967	U30-S01. Sample preparation for proteomic analysis, U30-S03. Protein identification by mass spectrometry (MS) or MS/MS, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments	0

10 de febrero de 2026

Comité de Coordinación de NANBIOSIS